EVO
Price
$4.47
Change
-$0.00 (-0.00%)
Updated
Dec 23, 04:59 PM (EDT)
93 days until earnings call
EVOK
Price
$4.96
Change
-$0.11 (-2.17%)
Updated
Dec 23, 04:59 PM (EDT)
Ad is loading...

EVO vs EVOK

Header iconEVO vs EVOK Comparison
Open Charts EVO vs EVOKBanner chart's image
Evotec SE
Price$4.47
Change-$0.00 (-0.00%)
Volume$874
CapitalizationN/A
Evoke Pharma
Price$4.96
Change-$0.11 (-2.17%)
Volume$100
CapitalizationN/A
EVO vs EVOK Comparison Chart
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. EVOK commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and EVOK is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Dec 24, 2024
Stock price -- (EVO: $4.46 vs. EVOK: $4.96)
Brand notoriety: EVO and EVOK are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 31% vs. EVOK: 3%
Market capitalization -- EVO: $2.77B vs. EVOK: $5.17M
EVO [@Pharmaceuticals: Other] is valued at $2.77B. EVOK’s [@Pharmaceuticals: Other] market capitalization is $5.17M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileEVOK’s FA Score has 0 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • EVOK’s FA Score: 0 green, 5 red.
According to our system of comparison, EVO is a better buy in the long-term than EVOK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while EVOK’s TA Score has 3 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 4 bearish.
  • EVOK’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, EVO is a better buy in the short-term than EVOK.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а -4.50% price change this week, while EVOK (@Pharmaceuticals: Other) price change was +8.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.13%. For the same industry, the average monthly price growth was -0.78%, and the average quarterly price growth was -8.74%.

Reported Earning Dates

EVO is expected to report earnings on Mar 27, 2025.

EVOK is expected to report earnings on Nov 08, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-0.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than EVOK($5.17M). EVOK (-60.646) and EVO (-61.978) have similar YTD gains . EVOK has higher annual earnings (EBITDA): -7.29M vs. EVO (-63.26M). EVO has more cash in the bank: 619M vs. EVOK (4.74M). EVOK has less debt than EVO: EVOK (5M) vs EVO (589M). EVO has higher revenues than EVOK: EVO (821M) vs EVOK (5.18M).
EVOEVOKEVO / EVOK
Capitalization2.77B5.17M53,549%
EBITDA-63.26M-7.29M867%
Gain YTD-61.978-60.646102%
P/E Ratio476.19N/A-
Revenue821M5.18M15,846%
Total Cash619M4.74M13,062%
Total Debt589M5M11,780%
FUNDAMENTALS RATINGS
EVO vs EVOK: Fundamental Ratings
EVO
EVOK
OUTLOOK RATING
1..100
824
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
6160
P/E GROWTH RATING
1..100
283
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVOK's Valuation (53) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (98) in the null industry. This means that EVOK’s stock grew somewhat faster than EVO’s over the last 12 months.

EVOK's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that EVOK’s stock grew similarly to EVO’s over the last 12 months.

EVO's SMR Rating (94) in the null industry is in the same range as EVOK (100) in the Pharmaceuticals Other industry. This means that EVO’s stock grew similarly to EVOK’s over the last 12 months.

EVOK's Price Growth Rating (60) in the Pharmaceuticals Other industry is in the same range as EVO (61) in the null industry. This means that EVOK’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for EVOK (83) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than EVOK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOEVOK
RSI
ODDS (%)
Bearish Trend 5 days ago
53%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
64%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
66%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
77%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGRTX25.980.20
+0.78%
Fidelity Mega Cap Stock
MIGOX26.450.19
+0.72%
Marsico Global Institutional
ABIYX14.010.09
+0.65%
AB International Value Advisor
RMFAX54.810.24
+0.44%
American Funds American Mutual R1
ESIFX11.87N/A
N/A
Eaton Vance Balanced R6

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
-0.22%
SNDL - EVO
42%
Loosely correlated
+2.78%
LFCR - EVO
29%
Poorly correlated
-2.90%
ACET - EVO
26%
Poorly correlated
-1.79%
ESPR - EVO
25%
Poorly correlated
+2.28%
PAHC - EVO
24%
Poorly correlated
-0.23%
More

EVOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVOK has been loosely correlated with RDHL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EVOK jumps, then RDHL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-2.17%
RDHL - EVOK
33%
Loosely correlated
-2.77%
NBIX - EVOK
28%
Poorly correlated
+1.16%
EOLS - EVOK
26%
Poorly correlated
-0.46%
PRFX - EVOK
25%
Poorly correlated
-15.85%
EVO - EVOK
24%
Poorly correlated
-0.22%
More